Immuno Modulatory Alpha Neutrophils (IMAN) is a next gen cancer therapy that uses neutrophils to attack cancer cells. Idea is to grow powerful neutrophilsfrom rare “super donors” who naturally have exceptionally strong immunity. By giving these lab-grown cells to patients, the therapy hopes to directly attack tumors and even help other treatments, like checkpoint inhibitors, work again when they’ve stopped being effective. First human trials are planned for 2026 in Galway, Ireland, with early results expected the following year and, if successful, the treatment could reach patients by 2030.
Super donor neutrophils are highly active immune cells from select healthy individuals with special cancer-killing power. They are being developed for next-generation cancer therapy to help destroy tumors when transfused into patients.